JPWO2023038037A1 - - Google Patents
Info
- Publication number
- JPWO2023038037A1 JPWO2023038037A1 JP2023546954A JP2023546954A JPWO2023038037A1 JP WO2023038037 A1 JPWO2023038037 A1 JP WO2023038037A1 JP 2023546954 A JP2023546954 A JP 2023546954A JP 2023546954 A JP2023546954 A JP 2023546954A JP WO2023038037 A1 JPWO2023038037 A1 JP WO2023038037A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021146461 | 2021-09-08 | ||
| PCT/JP2022/033487 WO2023038037A1 (ja) | 2021-09-08 | 2022-09-07 | 細胞の処理方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2023038037A1 true JPWO2023038037A1 (https=) | 2023-03-16 |
Family
ID=85507641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546954A Pending JPWO2023038037A1 (https=) | 2021-09-08 | 2022-09-07 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240366673A1 (https=) |
| EP (1) | EP4400576A4 (https=) |
| JP (1) | JPWO2023038037A1 (https=) |
| KR (1) | KR20240063899A (https=) |
| CN (1) | CN118103492A (https=) |
| AU (1) | AU2022342919A1 (https=) |
| TW (1) | TW202315937A (https=) |
| WO (1) | WO2023038037A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024234571A1 (en) * | 2023-03-15 | 2025-09-25 | Gaia Biomedicine Inc. | Solution for suspending cells and use thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015526088A (ja) * | 2012-08-13 | 2015-09-10 | アントフロゲネシス コーポレーション | ナチュラルキラー細胞及びその使用 |
| JP2018502114A (ja) * | 2014-12-31 | 2018-01-25 | アントフロゲネシス コーポレーション | ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法 |
| JP2018535666A (ja) * | 2015-10-15 | 2018-12-06 | セルラリティ インコーポレイテッド | ナチュラルキラー細胞およびilc3細胞ならびにそれらの使用 |
| WO2020196297A1 (ja) * | 2019-03-22 | 2020-10-01 | 株式会社ガイアバイオメディシン | 免疫細胞提供方法 |
| JP2021505207A (ja) * | 2017-12-05 | 2021-02-18 | セリアド エス.アー.Celyad S.A. | Nkg2dベースの受容体を発現する免疫細胞のフラトリサイドの減少 |
| US20210267190A1 (en) * | 2018-07-10 | 2021-09-02 | Nantkwest, Inc. | Cryopreservation |
| JP2022546484A (ja) * | 2019-08-28 | 2022-11-04 | ベクトン・ディキンソン・アンド・カンパニー | 延長可能な延長チューブを備えたカテーテルシステム |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4947948B1 (https=) | 1970-05-21 | 1974-12-18 | ||
| WO2002001952A1 (fr) | 2000-07-05 | 2002-01-10 | Hiromi Wada | Fluide de preservation pour cellules et tissus |
| JP4385158B2 (ja) | 2000-12-04 | 2009-12-16 | 株式会社リンフォテック | 細胞の保存液および該保存液を用いた細胞の保存方法 |
| JP4947948B2 (ja) | 2004-10-12 | 2012-06-06 | ニプロ株式会社 | 細胞保存液 |
| US20120149108A1 (en) | 2009-08-19 | 2012-06-14 | Masashige Tanabe | Cell preservation method |
| ES2652666T3 (es) * | 2011-12-22 | 2018-02-05 | Mogam Biotechnology Institute | Procedimiento de producción de linfocitos citolíticos naturales, linfocitos citolíticos naturales producidos de este modo y composición para el tratamiento de cánceres y enfermedades infecciosas que contienen los mismos |
| WO2013115322A1 (ja) | 2012-02-02 | 2013-08-08 | タカラバイオ株式会社 | 細胞の保存方法 |
| JP5432322B2 (ja) | 2012-05-08 | 2014-03-05 | 株式会社大塚製薬工場 | トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液 |
| JP6647240B2 (ja) | 2017-05-12 | 2020-02-14 | 米満 吉和 | 高活性nk細胞、およびその利用 |
| FR3074018B1 (fr) * | 2017-11-27 | 2020-09-11 | Lab Francais Du Fractionnement | Procede de cryoconservation de cellules a visee therapeutique |
| JP6543375B1 (ja) | 2018-03-27 | 2019-07-10 | 株式会社ガイアバイオメディシン | ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用 |
| CN113454207A (zh) * | 2018-11-30 | 2021-09-28 | 细胞结构公司 | 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞 |
| CN114615886A (zh) * | 2019-08-29 | 2022-06-10 | 得克萨斯大学体系董事会 | 细胞冷冻保存培养基 |
| JP7793284B2 (ja) | 2020-03-02 | 2026-01-05 | 株式会社ガイアバイオメディシン | 高活性nk細胞の処理方法 |
| EP4173640A4 (en) * | 2020-06-30 | 2024-08-14 | GAIA BioMedicine Inc. | METHOD FOR STABILIZING THE BINDING OF AN ANTIBODY ON AN NK CELL AND ASSOCIATED USE |
-
2022
- 2022-09-07 KR KR1020247008687A patent/KR20240063899A/ko active Pending
- 2022-09-07 CN CN202280058162.3A patent/CN118103492A/zh active Pending
- 2022-09-07 JP JP2023546954A patent/JPWO2023038037A1/ja active Pending
- 2022-09-07 EP EP22867359.6A patent/EP4400576A4/en active Pending
- 2022-09-07 TW TW111133861A patent/TW202315937A/zh unknown
- 2022-09-07 US US18/689,568 patent/US20240366673A1/en active Pending
- 2022-09-07 WO PCT/JP2022/033487 patent/WO2023038037A1/ja not_active Ceased
- 2022-09-07 AU AU2022342919A patent/AU2022342919A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015526088A (ja) * | 2012-08-13 | 2015-09-10 | アントフロゲネシス コーポレーション | ナチュラルキラー細胞及びその使用 |
| JP2018502114A (ja) * | 2014-12-31 | 2018-01-25 | アントフロゲネシス コーポレーション | ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法 |
| JP2018535666A (ja) * | 2015-10-15 | 2018-12-06 | セルラリティ インコーポレイテッド | ナチュラルキラー細胞およびilc3細胞ならびにそれらの使用 |
| JP2021505207A (ja) * | 2017-12-05 | 2021-02-18 | セリアド エス.アー.Celyad S.A. | Nkg2dベースの受容体を発現する免疫細胞のフラトリサイドの減少 |
| US20210267190A1 (en) * | 2018-07-10 | 2021-09-02 | Nantkwest, Inc. | Cryopreservation |
| WO2020196297A1 (ja) * | 2019-03-22 | 2020-10-01 | 株式会社ガイアバイオメディシン | 免疫細胞提供方法 |
| JP2022546484A (ja) * | 2019-08-28 | 2022-11-04 | ベクトン・ディキンソン・アンド・カンパニー | 延長可能な延長チューブを備えたカテーテルシステム |
Non-Patent Citations (2)
| Title |
|---|
| ‘VETERINARY PLASMA-LYTE A’, 2020年7月, [2022年11月2日検索], インターネット<HTTPS: //DAILYMED.NLM.N, JPN6022004743, ISSN: 0005834482 * |
| WILLIAMS, B. ET AL.: "NK-92 Therapy Is Well Tolerated, Has Minimal Toxicity and Shows Efficacy in a Phase I Trial of Patie", BLOOD, vol. vol.126, no.23, article no.4297, p.1-3, JPN6022047435, 2015, ISSN: 0005834481 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022342919A1 (en) | 2024-03-14 |
| CN118103492A (zh) | 2024-05-28 |
| US20240366673A1 (en) | 2024-11-07 |
| KR20240063899A (ko) | 2024-05-10 |
| EP4400576A4 (en) | 2025-10-15 |
| TW202315937A (zh) | 2023-04-16 |
| WO2023038037A1 (ja) | 2023-03-16 |
| EP4400576A1 (en) | 2024-07-17 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250430 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20250628 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250701 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260407 |